-+ 0.00%
-+ 0.00%
-+ 0.00%

Novocure wins CE mark for Optune Pax in locally advanced pancreatic cancer treatment

PUBT·06/30/2026 11:00:55
Listen to the news
Novocure wins CE mark for Optune Pax in locally advanced pancreatic cancer treatment
  • Novocure’s Optune Pax won CE Mark clearance for adults with locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.
  • PANOVA-3 showed median overall survival of 16.2 months versus 14.2 months on chemotherapy alone, supporting the EU authorization.
  • The company plans to launch Optune Pax in Germany in the coming weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260630829863) on June 30, 2026, and is solely responsible for the information contained therein.